
Core Insights - The company is on track to release topline data for the ATH434-201 randomized, double-blind Phase 2 clinical trial in January 2025, which is focused on early-stage Multiple System Atrophy (MSA) [1] - Positive interim data from the ATH434-202 Phase 2 clinical trial indicates that ATH434 may have the potential to modify disease progression in MSA [1][4] - The company appointed Abby Macnish Niven as Chief Financial Officer [1][15] - As of September 30, 2024, the company reported a cash balance of A$9.28 million with operating cash outflows of A$3.31 million for the quarter [1][3] Clinical Trial Updates - Interim results from the ATH434-202 trial suggest that 30% of participants had stable or improved clinical outcomes, indicating a potential disease-modifying effect [6][7] - The average change in Unified MSA Rating Scale Part I (UMSARS I) scores over 6 months was less than that observed in a historical group of untreated MSA patients, suggesting reduced disability [6] - The trial remains ongoing, with topline 12-month results expected in the first half of calendar year 2025 [8] Data Presentations - The company presented multiple data at the International Congress of Parkinson's Disease and Movement Disorders® (MDS), showcasing the potential of ATH434 in various neurological conditions [2][4] - The interim analysis included clinical and biomarker data on 7 participants treated with ATH434 for 6 months, demonstrating a favorable safety profile with no serious drug-related adverse events [5] Biomarker Insights - The stabilization of iron levels in specific brain regions and stable levels of Neurofilament light chain (NfL) in clinical responders suggest that ATH434 may slow neurodegeneration by modulating brain iron levels [7] - The bioMUSE natural history study continues to provide promising data to track MSA progression and characterize it in terms of various biomarkers [10][11] Corporate Activities - The company engaged in multiple investor activities, including a webinar and a presentation hosted by ShareCafe [16]